Citations

Clear

6274 citation(s) found for "To, Andrew".

Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors
Manjunath, Mohith , Yan, Jialu, Youn, Yeoan, Drucker, Kristen , Kollmeyer, Thomas M. , McKinney, Andrew , Zhang, Yi , Costello, J , Eckel‐Passow, Jeanette E. , Selvin, Paul R., Jenkins, Robert B. , Song, Jun S. , Drucker, Kristen L, Eckel-Passow, Jeanette, Kollmeyer, Thomas , Drucker, Kristen L , Zazubovich, Valter

Mayo Clinic

Neuro-Oncology | October 26, 2020 | Volume: 23 | Issue: 4 | Pages: 638-649

10.1093/neuonc/noaa248 | PMID 33130899 Get It

AbstractBackgroundLarge-scale genome-wide association studies (GWAS) have implicated thousands of germline genetic variants in modulating individuals’ risk to various diseases, including cancer. At least 25 risk loci have been identified for low-grade gliomas (LGGs), but their molecular functions remain largely unknown.MethodsWe hypothesized that GWAS loci contain causal single nucleotide polymorphisms (SNPs) that reside in accessible open chromatin regions and modulate the expression of target genes by perturbing the binding affinity of transcription factors (TFs). We performed an integrative analysis of genomic and epigenomic data from The Cancer Genome Atlas and other public repositories to identify candidate causal SNPs within linkage disequilibrium blocks of LGG GWAS loci. We assessed their potential regulatory role via in silico TF binding sequence perturbations, convolutional neural network trained on TF binding data, and simulated annealing–based interpretation methods.ResultsWe built an interactive website (http://education.knoweng.org/alg3/) summarizing the functional footprinting of 280 variants in 25 LGG GWAS regions, providing rich information for further computational and experimental scrutiny. We identified as case studies PHLDB1 and SLC25A26 as candidate target genes of rs12803321 and rs11706832, respectively, and predicted the GWAS variant rs648044 to be the causal SNP modulating ZBTB16, a known tumor suppressor in multiple cancers. We showed that rs648044 likely perturbed the binding affinity of the TF MAFF, as supported by RNA interference and in vitro MAFF binding experiments.ConclusionsThe identified candidate (causal SNP, target gene, TF) triplets and the accompanying resource will help accelerate our understanding of the molecular mechanisms underlying genetic risk factors for gliomas.
The current state of the platelet supply in the US and proposed options to decrease the risk of critical shortages
Stubbs, James R. , Homer, Mary J. , Silverman, Toby , Cap, Andrew P., Cap, Andrew P.

Mayo Clinic

Transfusion | October 24, 2020 | Volume: 61 | Issue: 1 | Pages: 303-312

10.1111/trf.16140 | PMID 33098328 Get It

AbstractDue to circumstances such as increased demand and an aging donor pool, the likelihood of critical platelet shortages is increasing. The platelet supply could be improved through the expansion of the donor pool, the identification and sustained utilization of high‐quality donors, and changes in component processing and storage that result in a longer platelet shelf‐life. Refrigerated platelets, stored at 1° to 6°C, have the potential to improve patient safety by decreasing the risk of bacterial contamination while concurrently allowing for a longer storage period (eg, 14 days) and improved hemostatic effectiveness in actively bleeding patients. An approach utilizing remuneration of apheresis platelet donors combined with pathogen reduction of the platelet components could be used as a means to increase the donor pool and identify and sustain safe, reliable, high‐quality donors. Remuneration might provide an incentive for underutilized populations (eg, individuals <30 years old) to enter the apheresis platelet donor population resulting in a significant expansion of the platelet donor pool. Over time, approaches such as the use of refrigerated platelets, platelet donor remuneration, and the application of pathogen reduction technology, might serve to attract a large, reliable, and safe donor base that provides platelet collections with high yields, longer shelf‐lives and, excellent hemostatic function.
S2894 Jaundice, Elevated Beta-Human Chorionic Gonadotropin, and Female Gender: Duodenal Choriocarcinoma, Not Pregnancy
Berry, Nick A., Sobrado, Javier, Mohan, Karthik , Berry, Bruce, Berry, Andrew C. , Berry, Bruce B.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S1517-S1517

10.14309/01.ajg.0000713624.51210.53 Get It

S2492 Hemolytic Anemia: A Rare Association With Acute Hepatitis B
Satyanarayana, Raj, Rosser, Barry, Zaver, Himesh B. , Wijarnpreecha, Karn , Pungpapong, Surakit , Rosser, Barry G., Keaveny, Andrew P.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S1317-S1317

10.14309/01.ajg.0000712016.32790.04 Get It

S0666 Reproductive Beliefs and Contraceptive Preferences of Women With Inflammatory Bowel Disease
Cannon, Rachel , Burdine, Lauren K. , Kulkarni, Amoli, Mahoney, Taylor F. , LeClair, Jessica , Farraye, Jennifer , Limdi, Jimmy K. , Canakis, Andrew , Wasan, Sharmeel K. , Woodhams, Elisabeth J. , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S334-S334

10.14309/01.ajg.0000704712.55131.3c Get It

S0053 Comparison of EUS-Guided Conventional Smear Cytology and Liquid Based Cytology in Pancreatic Lesions: A Systematic Review and Meta-Analysis
Keim, Lauren M., Khan, Shahab R. , Dhaliwal, Amaninder J., Shah, Aun R. , Bhogal, Neil, Mashiana, Harmeet S., Mashiana, Simran, Kassab, Lena L., Ponnada, Suresh, Bhat, Ishfaq , Singh, Shailender, Witt, Benjamin L., Chandan, Saurabh , Mohan, Babu P. , Ofosu, Andrew , Facciorusso, Antonio , Adler, Douglas G.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S26-S26

10.14309/01.ajg.0000702260.63492.84 Get It

Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake
Schaid, Daniel J. , Vachon, Celine M. , Cooke, Andrew , Kim, Christina , Sinnwell, Jason P. , Hasadsri, Linda , Stan, Daniela , Goldenberg, Benjamin A. , Neal, Lonzetta, Grenier, Debjani, Thicke, Lori A., Pruthi, Sandhya , Vachon, Celine M. , Sinnwell, Jason P , Stan, Daniela L , Goldenberg, Benjamin , Degnim, Amy C , Kim, Christina A , Kim, Julian O. , Couch, Fergus J. , Degnim, Amy C.

Mayo Clinic

Cancer Prevention Research | October 23, 2020 | Volume: 14 | Issue: 2 | Pages: 175-184

10.1158/1940-6207.capr-20-0154 | PMID 33097489 Get It

Abstract Endocrine therapy is underutilized to reduce breast cancer incidence among women at increased risk. Polygenic risk scores (PRSs) assessing 77 breast cancer genetic susceptibility loci personalizes risk estimates. We examined effect of personalized PRS breast cancer risk prediction on intention to take and endocrine therapy uptake among women at increased risk. Eligible participants had a 10-year breast cancer risk ≥5% by Tyrer–Cuzick model [International Breast Cancer Intervention Study (IBIS)] or ≥3.0 % 5-year Gail Model risk with no breast cancer history or hereditary breast cancer syndrome. Breast cancer risk was estimated, endocrine therapy options were discussed, and endocrine therapy intent was assessed at baseline. After genotyping, PRS-updated breast cancer risk estimates, endocrine therapy options, and intent to take endocrine therapy were reassessed; endocrine therapy uptake was assessed during follow-up. From March 2016 to October 2017, 151 patients were enrolled [median (range) age, 56.1 (36.0–76.4 years)]. Median 10-year and lifetime IBIS risks were 7.9% and 25.3%. Inclusion of PRS increased lifetime IBIS breast cancer risk estimates for 81 patients (53.6%) and reduced risk for 70 (46.4%). Of participants with increased breast cancer risk by PRS, 39 (41.9%) had greater intent to take endocrine therapy; of those with decreased breast cancer risk by PRS, 28 (46.7%) had less intent to take endocrine therapy (P &lt; 0.001). On multivariable regression, increased breast cancer risk by PRS was associated with greater intent to take endocrine therapy (P &lt; 0.001). Endocrine therapy uptake was greater among participants with increased breast cancer risk by PRS (53.4%) than with decreased risk (20.9%; P &lt; 0.001). PRS testing influenced intent to take and endocrine therapy uptake. Assessing PRS effect on endocrine therapy adherence is needed. Prevention Relevance: Counseling women at increased breast cancer risk using polygenic risk score (PRS) risk estimates can significantly impact preventive endocrine therapy uptake. Further development of PRS testing to personalize breast cancer risk assessments and endocrine therapy counselling may serve to potentially reduce the incidence of breast cancer in the future.
Comparison of EUS-guided conventional smear and liquid-based cytology in pancreatic lesions: A systematic review and meta-analysis
Khan, Shahab R. , Ofosu, Andrew , Dhaliwal, Amaninder, Shah, Aun R. , Bhogal, Neil, Mashiana, Harmeet S., Mashiana, Simran, Kassab, Lena L., Ponnada, Suresh, Bhat, Ishfaq , Singh, Shailender, Witt, Benjamin L., Chandan, Saurabh , Mohan, Babu P. , Facciorusso, Antonio , Adler, Douglas G.

Mayo Clinic

Endoscopy International Open | October 22, 2020 | Volume: 08 | Issue: 11 | Pages: E1611-E1622

10.1055/a-1240-0027 | PMID 33140017 Get It

Abstract Background and study aims Endoscopic ultrasound (EUS)-guided fine-needle aspiration (EUS-FNA) has limitations of inadequate sampling and false-negative results for malignancy. It has been performed using conventional smear (CS) cytology with rapid on-site evaluation (ROSE) with reasonable diagnostic accuracy. An alternative to ROSE is liquid-based cytology (LBC). Commonly used LBC techniques include precipitation-based (SurePath™) and filtration-based (ThinPrep®, CellPrep®). Data regarding the diagnostic efficacy of LBC compared with CS are limited. Methods Multiple databases were searched through March 2020 to identify studies reporting diagnostic yield of EUS-guided CS and LBC in pancreatic lesions. Pooled diagnostic odds and rates of performance for the cytologic diagnoses of benign, suspicious, and malignant lesions were calculated. Diagnostic efficacy was evaluated by pooled rates of accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Results Nine studies with a total of 1308 patients were included in our final analysis. Pooled diagnostic odds of CS cytology were 1.69 (CI 1.02–2.79) and 0.39 (CI 0.19–0.8) for malignant lesions when compared to filtration-based and precipitation-based LBC techniques, respectively. For CS, precipitation-based and filtration-based LBC, pooled diagnostic accuracy was 79.7 %, 85.2 %, 77.3 %, sensitivity was 79.2 %, 83.6 %, 68.3 %, and specificity was 99.4 %, 99.5 %, 99.5 %, respectively. Conclusions The precipitation-based LBC technique (SurePath™) had superior diagnostic odds for malignant pancreatic lesions compared with CS cytology in the absence of ROSE. It showed superior accuracy and sensitivity, but comparable specificity and PPV. Diagnostic odds of CS cytology in the absence of ROSE were superior to the filtration-based LBC technique (ThinPrep®, Cellprep®) for diagnosing malignant pancreatic lesions.
Efficacy and safety of endoscopic ultrasound-guided pancreatic duct drainage (EUS-PDD): A systematic review and meta-analysis of 714 patients
Khan, Shahab R. , Kassab, Lena L., Ponnada, Suresh, Ofosu, Andrew , Bhat, Ishfaq , Singh, Shailender, Chandan, Saurabh , Mohan, Babu P. , Adler, Douglas G.

Mayo Clinic

Endoscopy International Open | October 22, 2020 | Volume: 08 | Issue: 11 | Pages: E1664-E1672

10.1055/a-1236-3350 | PMID 33140022 Get It

Abstract Background and study aims Endoscopic ultrasound guided pancreatic duct drainage (EUS-PDD) is a minimal-invasive therapeutic option to surgery and in patients with failed endoscopic retrograde pancreatography (ERP). The aim of this review was to quantitatively appraise the clinical outcomes of EUS-PDD by meta-analysis methods. Methods We searched multiple databases from inception through March 2020 to identify studies that reported on EUS-PDD. Pooled rates of technical success, successful drainage of pancreatic duct, clinical success, and adverse events were calculated. Study heterogeneity was assessed using I2% and 95 % prediction interval. Results A total of 22 studies (714 patients) were included. The pooled rate of technical success in EUS-PDD was 84.8 % (95 % CI 79.1–89.2). The pooled rate of successful PD drained by EUS-PDD was 77.5 % (95 % CI 63.1–87.4). The pooled rate of clinical success of EUS-PDD was 89.2 % (95 % CI 82.1–93.7). The pooled rate of all adverse events was 18.1 % (95 % CI 14.2–22.9). On sub-group analysis, the pooled technical success and clinical success of EUS-PDD from Japanese data were considerably superior (91.2 %, 83–95.6 & 92.5 %, 83.9–96.7, respectively). The pooled rate of post EUS-PDD acute pancreatitis was 6.6 % (95 % CI 4.5–9.4), bleeding was 4.1 % (95 % CI 2.7–6.2), perforation and/or pneumoperitoneum was 3.1 % (95 % CI 1.9–5), pancreatic leak and/or pancreatic fluid collection was 2.3 % (95 % CI 1.4–4), and infection was 2.8 % (95 % CI 1.7–4.6). Conclusion EUS-PDD demonstrates high technical success and clinical success rates with acceptable adverse events. Technical success was especially high for anastomotic strictures.
Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients
Teaford, Hilary R. , Mara, Kristin C. , Frazee, Erin N. , O'horo, John, Frazee, Erin N , Mara, Kristin C , Stevens, Ryan W. , Rule, Andrew D. , Kashani, Kianoush , Lieske, John C. , O’Horo, John C.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 22, 2020 | Volume: 65 | Issue: 1 | Pages: No page available

10.1128/aac.01487-20 | PMID 33106257 Get It

The use of the kidney function biomarker cystatin C (cysC) can improve the accuracy of vancomycin dosing for target trough attainment in nonobese patients. It is unknown whether cysC can also improve vancomycin target trough attainment in overweight and obese patients. We conducted a retrospective observational study of overweight or obese hospitalized adults with stable renal function administered intravenous vancomycin between January 2011 and July 2019. Linear regression models were used to predict initial steady-state vancomycin troughs using several factors, including various cysC- and serum creatinine (SCr)-based estimates of kidney function.